Mereo BioPharma Group plc — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Lewicki John A. | Chief Scientific Officer | Sale | 5,212 | $4.47 | $23,298 | 89,567 | Sep 13, 2024 |
| Fox Christine Ann | Chief Financial Officer | Sale | 9,128 | $4.47 | $40,802 | 108,443 | Sep 13, 2024 |
| Hughes-Wilson Alexandra | See Remarks | Sale | 7,769 | $4.47 | $34,727 | 190,816 | Sep 13, 2024 |
| Scots-Knight Denise | Chief Executive Officer | Sale | 60,046 | $4.22 | $253,394 | 808,921 | Sep 12, 2024 |
| Sermon Charles | General Counsel | Sale | 20,946 | $4.22 | $88,392 | 219,061 | Sep 12, 2024 |
| Sermon Charles | General Counsel | Option Exercise | 65,600 | — | — | 249,987 | Sep 11, 2024 |
| Fox Christine Ann | Chief Financial Officer | Option Exercise | 60,000 | — | — | 117,571 | Sep 11, 2024 |
| Lewicki John A. | Chief Scientific Officer | Option Exercise | 46,000 | — | — | 94,779 | Sep 11, 2024 |
| Scots-Knight Denise | Chief Executive Officer | Option Exercise | 188,060 | — | — | 897,578 | Sep 11, 2024 |
| Hughes-Wilson Alexandra | See Remarks | Option Exercise | 75,000 | $1.01 | $75,750 | 242,881 | Sep 11, 2024 |
| PAKIANATHAN DEEPIKA | — | Option Exercise | 1,825 | $3.00 | $5,475 | 1,825 | Aug 22, 2024 |
| Sermon Charles | General Counsel | Sale | 14,202 | $3.69 | $52,405 | 216,574 | Jun 26, 2024 |
| Fox Christine Ann | Chief Financial Officer | Sale | 12,990 | $3.69 | $47,933 | 87,010 | Jun 26, 2024 |
| Hughes-Wilson Alexandra | See Remarks | Sale | 10,134 | $3.69 | $37,394 | 57,516 | Jun 26, 2024 |
| Lewicki John A. | Chief Scientific Officer | Sale | 16,808 | $3.39 | $56,979 | 48,779 | Jun 25, 2024 |
| Scots-Knight Denise | Chief Executive Officer | Sale | 92,273 | $3.39 | $312,805 | 709,518 | Jun 25, 2024 |
| Lewicki John A. | Chief Scientific Officer | Option Exercise | 69,000 | — | — | 73,003 | Jun 21, 2024 |
| Scots-Knight Denise | Chief Executive Officer | Option Exercise | 282,090 | — | — | 842,503 | Jun 21, 2024 |
| Sermon Charles | General Counsel | Option Exercise | 98,400 | — | — | 230,776 | Jun 21, 2024 |
| Fox Christine Ann | Chief Financial Officer | Option Exercise | 90,000 | — | — | 100,000 | Jun 21, 2024 |
| Hughes-Wilson Alexandra | See Remarks | Option Exercise | 60,000 | — | — | 67,650 | Jun 21, 2024 |
| WYZGA MICHAEL S | — | Award / Grant | 25,050 | $3.99 | $99,950 | 25,050 | Jun 17, 2024 |
| Bender Jeremy | — | Award / Grant | 12,550 | $3.99 | $50,075 | 12,550 | Jun 17, 2024 |
| Hughes-Wilson Alexandra | See Remarks | Sale | 50,082 | $2.94 | $147,241 | 32,568 | May 22, 2024 |